{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:39:01Z","timestamp":1778891941422,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Outbreak of the new type coronavirus infection, known as coronavirus infection 2019 (COVID-19), has begun in December 2019, in Wuhan, China. As of today, 3 April 2020, 972,640 people affected and 50,325 people died from Severe Acute Respiratory Syndrome-Coronavirus 2. There is not any standard treatment for coronavirus infection 2019; however, there are promising data for hydroxychloroquine and some anti-retroviral drugs. Programmed death-1 (PD-1)\/programmed death ligand-1 (PDL-1) pathway is an important target for the cancer immunotherapy. However, there is a robust pre-clinical and clinical data regarding inhibitor effect of this pathway on the acute or chronic viral infections. Thus, blockade of this pathway may lead to an anti-viral effect and decrease viral load. Here, we report the clinical course of coronavirus infection 2019 infection of a patient in whom older aged, having multiple co-morbidities, and taking nivolumab for metastatic malignant melanoma. In contrast to her older age, comorbidities, and cancer diagnosis, she was in a good condition, and there was also no pneumonia finding. We think that this good clinical course of coronavirus infection 2019 infection may be related to blockade of PD-1\/PDL-1 pathway with nivolumab. It is impossible to say that blockade of PD-1\/PDL-1pathway is a treatment option for COVID-19; however, we want to share our experience.<\/jats:p>","DOI":"10.1177\/1078155220924084","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T04:26:14Z","timestamp":1589862374000},"page":"1289-1294","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-5930","authenticated-orcid":false,"given":"Emre","family":"Yeked\u00fcz","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Ankara University, Ankara, Turkey"},{"name":"Ankara University Cancer Research Institute, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beng\u00fc","family":"Dursun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara University, Ankara, Turkey"},{"name":"Ankara University Cancer Research Institute, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcle \u00c7","family":"Ayd\u0131n","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Clinical Microbiology, Ankara University, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sat\u0131 C","family":"Yazgan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ankara University, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halis H","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Radiology, Ankara University, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpay","family":"Azap","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Clinical Microbiology, Ankara University, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcng\u00f6r","family":"Utkan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara University, Ankara, Turkey"},{"name":"Ankara University Cancer Research Institute, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-9887","authenticated-orcid":false,"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara University, Ankara, Turkey"},{"name":"Ankara University Cancer Research Institute, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"bibr1-1078155220924084","unstructured":"WHO. Director-General\u2019s opening remarks at the media briefing on COVID-19, www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19 (2020, accessed 11 March 2020)."},{"key":"bibr2-1078155220924084","unstructured":"WHO. Coronavirus disease (COVID-19) outbreak situation 2020, www.who.int\/emergencies\/diseases\/novel-coronavirus-2019 (2020, accessed 3 April 2020)."},{"key":"bibr3-1078155220924084","doi-asserted-by":"crossref","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention.\n                      JAMA.\n                      Epub ahead of print 24 February 2020. DOI: 10.1001\/jama.2020.2648.","DOI":"10.1001\/jama.2020.2648"},{"key":"bibr4-1078155220924084","unstructured":"NCI. Age and cancer risk 2020, www.cancer.gov\/about-cancer\/causes-prevention\/risk\/age (2020, accessed 3 April 2020)."},{"key":"bibr5-1078155220924084","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6"},{"key":"bibr6-1078155220924084","first-page":"e3700","volume":"10","author":"Sahni S","year":"2018","journal-title":"Cureus"},{"key":"bibr7-1078155220924084","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0743-4"},{"key":"bibr8-1078155220924084","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.022"},{"key":"bibr9-1078155220924084","doi-asserted-by":"publisher","DOI":"10.1038\/nature04444"},{"key":"bibr10-1078155220924084","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1718217115"},{"key":"bibr11-1078155220924084","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00207"},{"key":"bibr12-1078155220924084","doi-asserted-by":"publisher","DOI":"10.1172\/JCI62860"},{"key":"bibr13-1078155220924084","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814547204"},{"key":"bibr14-1078155220924084","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier JC, Parola P, et\u00a0al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.\n                      Int J Antimicrob Agents.\n                      Epub ahead of print 20 March 2020. DOI: 10.1016\/j.ijantimicag.2020.105949.","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"bibr15-1078155220924084","doi-asserted-by":"crossref","unstructured":"Molina JM, Delaugerre C, Goff JL, et\u00a0al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.\n                      Med Mal Infect.\n                      Epub ahead of print 30 March 2020. DOI: 10.1016\/j.medmal.2020.03.006.","DOI":"10.1016\/j.medmal.2020.03.006"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220924084","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220924084","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220924084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:02Z","timestamp":1777688582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220924084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1177\/1078155220924084"],"URL":"https:\/\/doi.org\/10.1177\/1078155220924084","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]}}}